nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Bilirubin total increased—Epirubicin—sarcoma	0.0305	0.0305	CcSEcCtD
Oritavancin—Bilirubin total increased—Doxorubicin—sarcoma	0.0282	0.0282	CcSEcCtD
Oritavancin—Induration—Etoposide—sarcoma	0.0244	0.0244	CcSEcCtD
Oritavancin—Extravasation—Thiotepa—sarcoma	0.0174	0.0174	CcSEcCtD
Oritavancin—Extravasation—Dactinomycin—sarcoma	0.0173	0.0173	CcSEcCtD
Oritavancin—Hyperuricaemia—Thiotepa—sarcoma	0.0164	0.0164	CcSEcCtD
Oritavancin—Blood bilirubin increased—Thiotepa—sarcoma	0.0161	0.0161	CcSEcCtD
Oritavancin—Blood uric acid increased—Thiotepa—sarcoma	0.0155	0.0155	CcSEcCtD
Oritavancin—Extravasation—Vincristine—sarcoma	0.0154	0.0154	CcSEcCtD
Oritavancin—Extravasation—Mitoxantrone—sarcoma	0.015	0.015	CcSEcCtD
Oritavancin—Hyperuricaemia—Vincristine—sarcoma	0.0145	0.0145	CcSEcCtD
Oritavancin—Hyperuricaemia—Mitoxantrone—sarcoma	0.0141	0.0141	CcSEcCtD
Oritavancin—Blood bilirubin increased—Mitoxantrone—sarcoma	0.0139	0.0139	CcSEcCtD
Oritavancin—Blood uric acid increased—Vincristine—sarcoma	0.0137	0.0137	CcSEcCtD
Oritavancin—Blood uric acid increased—Mitoxantrone—sarcoma	0.0134	0.0134	CcSEcCtD
Oritavancin—Extravasation—Etoposide—sarcoma	0.0125	0.0125	CcSEcCtD
Oritavancin—Cellulitis—Etoposide—sarcoma	0.012	0.012	CcSEcCtD
Oritavancin—Hyperuricaemia—Etoposide—sarcoma	0.0118	0.0118	CcSEcCtD
Oritavancin—Blood uric acid increased—Etoposide—sarcoma	0.0111	0.0111	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Thiotepa—sarcoma	0.00993	0.00993	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Dactinomycin—sarcoma	0.00986	0.00986	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Thiotepa—sarcoma	0.00973	0.00973	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Vincristine—sarcoma	0.00881	0.00881	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Mitoxantrone—sarcoma	0.00858	0.00858	CcSEcCtD
Oritavancin—Infestation NOS—Thiotepa—sarcoma	0.0085	0.0085	CcSEcCtD
Oritavancin—Infestation—Thiotepa—sarcoma	0.0085	0.0085	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Mitoxantrone—sarcoma	0.0084	0.0084	CcSEcCtD
Oritavancin—Abscess—Epirubicin—sarcoma	0.00773	0.00773	CcSEcCtD
Oritavancin—Connective tissue disorder—Thiotepa—sarcoma	0.0075	0.0075	CcSEcCtD
Oritavancin—Erythema multiforme—Dactinomycin—sarcoma	0.00716	0.00716	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—sarcoma	0.00715	0.00715	CcSEcCtD
Oritavancin—Cardiac disorder—Thiotepa—sarcoma	0.00708	0.00708	CcSEcCtD
Oritavancin—Extravasation—Epirubicin—sarcoma	0.00701	0.00701	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Etoposide—sarcoma	0.00699	0.00699	CcSEcCtD
Oritavancin—Immune system disorder—Thiotepa—sarcoma	0.00689	0.00689	CcSEcCtD
Oritavancin—Mediastinal disorder—Thiotepa—sarcoma	0.00688	0.00688	CcSEcCtD
Oritavancin—Bronchospasm—Etoposide—sarcoma	0.00673	0.00673	CcSEcCtD
Oritavancin—Cellulitis—Epirubicin—sarcoma	0.00673	0.00673	CcSEcCtD
Oritavancin—Connective tissue disorder—Vincristine—sarcoma	0.00665	0.00665	CcSEcCtD
Oritavancin—Malnutrition—Thiotepa—sarcoma	0.00664	0.00664	CcSEcCtD
Oritavancin—Hyperuricaemia—Epirubicin—sarcoma	0.00659	0.00659	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—sarcoma	0.00649	0.00649	CcSEcCtD
Oritavancin—Blood bilirubin increased—Epirubicin—sarcoma	0.00647	0.00647	CcSEcCtD
Oritavancin—Cardiac disorder—Vincristine—sarcoma	0.00628	0.00628	CcSEcCtD
Oritavancin—Blood uric acid increased—Epirubicin—sarcoma	0.00623	0.00623	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—sarcoma	0.00622	0.00622	CcSEcCtD
Oritavancin—Anaemia—Thiotepa—sarcoma	0.00614	0.00614	CcSEcCtD
Oritavancin—Infestation NOS—Etoposide—sarcoma	0.0061	0.0061	CcSEcCtD
Oritavancin—Infestation—Etoposide—sarcoma	0.0061	0.0061	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—sarcoma	0.0061	0.0061	CcSEcCtD
Oritavancin—Mediastinal disorder—Vincristine—sarcoma	0.0061	0.0061	CcSEcCtD
Oritavancin—Anaemia—Dactinomycin—sarcoma	0.00609	0.00609	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—sarcoma	0.00598	0.00598	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—sarcoma	0.00576	0.00576	CcSEcCtD
Oritavancin—Myalgia—Thiotepa—sarcoma	0.00565	0.00565	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00562	0.00562	CcSEcCtD
Oritavancin—Myalgia—Dactinomycin—sarcoma	0.00561	0.00561	CcSEcCtD
Oritavancin—Anaemia—Vincristine—sarcoma	0.00544	0.00544	CcSEcCtD
Oritavancin—Infection—Thiotepa—sarcoma	0.00538	0.00538	CcSEcCtD
Oritavancin—Infection—Dactinomycin—sarcoma	0.00534	0.00534	CcSEcCtD
Oritavancin—Nervous system disorder—Thiotepa—sarcoma	0.00532	0.00532	CcSEcCtD
Oritavancin—Anaemia—Mitoxantrone—sarcoma	0.0053	0.0053	CcSEcCtD
Oritavancin—Tachycardia—Thiotepa—sarcoma	0.00529	0.00529	CcSEcCtD
Oritavancin—Skin disorder—Thiotepa—sarcoma	0.00526	0.00526	CcSEcCtD
Oritavancin—Erythema multiforme—Etoposide—sarcoma	0.00518	0.00518	CcSEcCtD
Oritavancin—Cardiac disorder—Etoposide—sarcoma	0.00509	0.00509	CcSEcCtD
Oritavancin—Myalgia—Vincristine—sarcoma	0.00501	0.00501	CcSEcCtD
Oritavancin—Immune system disorder—Etoposide—sarcoma	0.00495	0.00495	CcSEcCtD
Oritavancin—Mediastinal disorder—Etoposide—sarcoma	0.00494	0.00494	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00494	0.00494	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.0049	0.0049	CcSEcCtD
Oritavancin—Myalgia—Mitoxantrone—sarcoma	0.00488	0.00488	CcSEcCtD
Oritavancin—Infection—Vincristine—sarcoma	0.00477	0.00477	CcSEcCtD
Oritavancin—Nervous system disorder—Vincristine—sarcoma	0.00471	0.00471	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Thiotepa—sarcoma	0.00468	0.00468	CcSEcCtD
Oritavancin—Infection—Mitoxantrone—sarcoma	0.00465	0.00465	CcSEcCtD
Oritavancin—Tachycardia—Mitoxantrone—sarcoma	0.00457	0.00457	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—sarcoma	0.00455	0.00455	CcSEcCtD
Oritavancin—Skin disorder—Mitoxantrone—sarcoma	0.00455	0.00455	CcSEcCtD
Oritavancin—Anaemia—Etoposide—sarcoma	0.00441	0.00441	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vincristine—sarcoma	0.00438	0.00438	CcSEcCtD
Oritavancin—Urticaria—Thiotepa—sarcoma	0.00431	0.00431	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00426	0.00426	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—sarcoma	0.00421	0.00421	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vincristine—sarcoma	0.00415	0.00415	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00403	0.00403	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.004	0.004	CcSEcCtD
Oritavancin—Hypersensitivity—Thiotepa—sarcoma	0.00399	0.00399	CcSEcCtD
Oritavancin—Hypersensitivity—Dactinomycin—sarcoma	0.00396	0.00396	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—sarcoma	0.00392	0.00392	CcSEcCtD
Oritavancin—Infection—Etoposide—sarcoma	0.00387	0.00387	CcSEcCtD
Oritavancin—Pruritus—Thiotepa—sarcoma	0.00383	0.00383	CcSEcCtD
Oritavancin—Tachycardia—Etoposide—sarcoma	0.0038	0.0038	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—sarcoma	0.0038	0.0038	CcSEcCtD
Oritavancin—Skin disorder—Etoposide—sarcoma	0.00378	0.00378	CcSEcCtD
Oritavancin—Urticaria—Mitoxantrone—sarcoma	0.00372	0.00372	CcSEcCtD
Oritavancin—Diarrhoea—Thiotepa—sarcoma	0.00371	0.00371	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.0037	0.0037	CcSEcCtD
Oritavancin—Diarrhoea—Dactinomycin—sarcoma	0.00368	0.00368	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.00362	0.00362	CcSEcCtD
Oritavancin—Dizziness—Thiotepa—sarcoma	0.00358	0.00358	CcSEcCtD
Oritavancin—Hypersensitivity—Vincristine—sarcoma	0.00354	0.00354	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—sarcoma	0.00352	0.00352	CcSEcCtD
Oritavancin—Hypersensitivity—Mitoxantrone—sarcoma	0.00345	0.00345	CcSEcCtD
Oritavancin—Vomiting—Thiotepa—sarcoma	0.00345	0.00345	CcSEcCtD
Oritavancin—Infestation—Epirubicin—sarcoma	0.00342	0.00342	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—sarcoma	0.00342	0.00342	CcSEcCtD
Oritavancin—Vomiting—Dactinomycin—sarcoma	0.00342	0.00342	CcSEcCtD
Oritavancin—Rash—Thiotepa—sarcoma	0.00342	0.00342	CcSEcCtD
Oritavancin—Dermatitis—Thiotepa—sarcoma	0.00341	0.00341	CcSEcCtD
Oritavancin—Headache—Thiotepa—sarcoma	0.0034	0.0034	CcSEcCtD
Oritavancin—Rash—Dactinomycin—sarcoma	0.00339	0.00339	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Etoposide—sarcoma	0.00336	0.00336	CcSEcCtD
Oritavancin—Diarrhoea—Vincristine—sarcoma	0.00329	0.00329	CcSEcCtD
Oritavancin—Nausea—Thiotepa—sarcoma	0.00322	0.00322	CcSEcCtD
Oritavancin—Diarrhoea—Mitoxantrone—sarcoma	0.0032	0.0032	CcSEcCtD
Oritavancin—Nausea—Dactinomycin—sarcoma	0.0032	0.0032	CcSEcCtD
Oritavancin—Dizziness—Vincristine—sarcoma	0.00318	0.00318	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—sarcoma	0.00317	0.00317	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—sarcoma	0.00317	0.00317	CcSEcCtD
Oritavancin—Urticaria—Etoposide—sarcoma	0.00309	0.00309	CcSEcCtD
Oritavancin—Vomiting—Vincristine—sarcoma	0.00306	0.00306	CcSEcCtD
Oritavancin—Rash—Vincristine—sarcoma	0.00303	0.00303	CcSEcCtD
Oritavancin—Dermatitis—Vincristine—sarcoma	0.00303	0.00303	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—sarcoma	0.00303	0.00303	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—sarcoma	0.00302	0.00302	CcSEcCtD
Oritavancin—Headache—Vincristine—sarcoma	0.00301	0.00301	CcSEcCtD
Oritavancin—Vomiting—Mitoxantrone—sarcoma	0.00298	0.00298	CcSEcCtD
Oritavancin—Rash—Mitoxantrone—sarcoma	0.00295	0.00295	CcSEcCtD
Oritavancin—Dermatitis—Mitoxantrone—sarcoma	0.00295	0.00295	CcSEcCtD
Oritavancin—Headache—Mitoxantrone—sarcoma	0.00293	0.00293	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—sarcoma	0.0029	0.0029	CcSEcCtD
Oritavancin—Hypersensitivity—Etoposide—sarcoma	0.00287	0.00287	CcSEcCtD
Oritavancin—Nausea—Vincristine—sarcoma	0.00285	0.00285	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—sarcoma	0.00285	0.00285	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—sarcoma	0.0028	0.0028	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—sarcoma	0.00279	0.00279	CcSEcCtD
Oritavancin—Nausea—Mitoxantrone—sarcoma	0.00278	0.00278	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—sarcoma	0.00277	0.00277	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—sarcoma	0.00277	0.00277	CcSEcCtD
Oritavancin—Pruritus—Etoposide—sarcoma	0.00275	0.00275	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—sarcoma	0.00269	0.00269	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—sarcoma	0.00267	0.00267	CcSEcCtD
Oritavancin—Diarrhoea—Etoposide—sarcoma	0.00266	0.00266	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—sarcoma	0.00264	0.00264	CcSEcCtD
Oritavancin—Dizziness—Etoposide—sarcoma	0.00257	0.00257	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—sarcoma	0.00257	0.00257	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—sarcoma	0.00256	0.00256	CcSEcCtD
Oritavancin—Vomiting—Etoposide—sarcoma	0.00248	0.00248	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—sarcoma	0.00247	0.00247	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—sarcoma	0.00247	0.00247	CcSEcCtD
Oritavancin—Rash—Etoposide—sarcoma	0.00245	0.00245	CcSEcCtD
Oritavancin—Dermatitis—Etoposide—sarcoma	0.00245	0.00245	CcSEcCtD
Oritavancin—Headache—Etoposide—sarcoma	0.00244	0.00244	CcSEcCtD
Oritavancin—Nausea—Etoposide—sarcoma	0.00231	0.00231	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—sarcoma	0.00229	0.00229	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—sarcoma	0.00228	0.00228	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00226	0.00226	CcSEcCtD
Oritavancin—Infection—Epirubicin—sarcoma	0.00217	0.00217	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—sarcoma	0.00214	0.00214	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—sarcoma	0.00213	0.00213	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—sarcoma	0.00212	0.00212	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—sarcoma	0.00211	0.00211	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00209	0.00209	CcSEcCtD
Oritavancin—Infection—Doxorubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00199	0.00199	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—sarcoma	0.00198	0.00198	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—sarcoma	0.00197	0.00197	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—sarcoma	0.00196	0.00196	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—sarcoma	0.00188	0.00188	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00184	0.00184	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00174	0.00174	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—sarcoma	0.00173	0.00173	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—sarcoma	0.00161	0.00161	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—sarcoma	0.0016	0.0016	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—sarcoma	0.00154	0.00154	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—sarcoma	0.00149	0.00149	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—sarcoma	0.00149	0.00149	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—sarcoma	0.00144	0.00144	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—sarcoma	0.00143	0.00143	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—sarcoma	0.00139	0.00139	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—sarcoma	0.00138	0.00138	CcSEcCtD
Oritavancin—Rash—Epirubicin—sarcoma	0.00138	0.00138	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Oritavancin—Headache—Epirubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—sarcoma	0.00134	0.00134	CcSEcCtD
Oritavancin—Nausea—Epirubicin—sarcoma	0.0013	0.0013	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Oritavancin—Rash—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Oritavancin—Headache—Doxorubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—sarcoma	0.0012	0.0012	CcSEcCtD
